OncoResponse Mines PD-1 Therapy “Elite Responders” For IO Breakthroughs

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Emerging Company Profile: Harvesting blood and tissue samples from patients treated with PD-1 immunotherapy, OncoResponse is developing antibodies it believes can transform cold solid tumors into hot.

Tumor microenvironment, OncoResponse profile
OncoResponse's technology focuses on the tumor microenvironment and turning "cold" tumors "hot" • Source: Alamy

To hear OncoResponse Inc. CEO Clifford Stocks tell it, his company is “approaching that interesting time point where pharma likes to partner” as it readies lead candidate OR2805 for efficacy studies in solid tumors. Currently in Phase I, OR2805 is derived from B-cells harvested from an “elite responder” to a commercial anti-PD-1 therapy and may offer an approach for transforming “cold” tumors into immuno-responsive or “hot” ones.

With an antibody-discovering platform technology that Theraclone Sciences, Inc. once used in novel anti-infectious R&D, OncoResponse scientists can interrogate...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Emerging Company Profiles

Scrip-Business (Free-1): Top-Selling Drugs 2024: Keytruda, Ozempic And Dupixent Dominate

 
• By Nabil

Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.

Empress Looks To The Body’s Internal Chemistry For Drug Leads

 
• By Joseph Haas

Emerging Company Profile: Backed by Flagship Pioneering, Empress deploys its Chemilogics platform to seek leads for small molecule therapies in inflammation, immunology, cancer and metabolic disease.

Mythic Therapeutics Faces An Acid Test

 
• By Elizabeth Cairns

Emerging Company Profile: Efficacy data on the young group’s first pH-engineered antibody-drug conjugate could come next year, and potential partners will be watching.    

Emergex Goes To Battle Against ‘The Nasties’

 
• By Alaric DeArment

Emerging Company Profile: The eight-year-old vaccine firm is planning clinical trials in the Philippines and Brazil to see how its synthetic viral peptide vaccine technology stands up against coronaviruses and dengue fever.

More from Start-Ups & SMEs

Pathalys Raises $105m To Pave Path Toward US Commercialization

 
• By Mandy Jackson

The start-up launched last year with Phase III-ready upacicalcet, which has nearly completed two pivotal trials in secondary hyperparathyroidism and for which it has exclusive rights outside of Asia.

Empress Looks To The Body’s Internal Chemistry For Drug Leads

 
• By Joseph Haas

Emerging Company Profile: Backed by Flagship Pioneering, Empress deploys its Chemilogics platform to seek leads for small molecule therapies in inflammation, immunology, cancer and metabolic disease.

Syros’s AML Failure Sparks MDS Program Jitters, But Fears May Be Overblown

 
• By Alaric DeArment

Discontinuation of the AML study created concern about potential readthrough to a pivotal MDS trial, but the company and analysts pointed out differences in the diseases.